Crinetics Pharmaceuticals Inc.(CRNX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRNX Crinetics Pharmaceuticals Inc.

美国阵亡战士纪念日休市 05-22 16:00:00 EDT

36.80

-0.29

-0.78%

盘后36.80

+0.000.00%

16:10 EDT

最高37.80	最低36.64	成交量70.24万
今开37.22	昨收37.09	日振幅3.13%
总市值38.80亿	流通市值35.45亿	总股本1.05亿
成交额2,595万	换手率0.73%	流通股本9,632万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRNX","market":"US","secType":"STK","nameCN":"Crinetics Pharmaceuticals Inc.","latestPrice":36.8,"timestamp":1779480000000,"preClose":37.09,"halted":0,"volume":702431,"hourTrading":{"tag":"盘后","latestPrice":36.8,"preClose":36.8,"latestTime":"16:10 EDT","volume":23539,"amount":866235.2,"timestamp":1779480604911,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.007818819088703322,"floatShares":96322500,"shares":105439535,"eps":-5.129138,"marketStatus":"美国阵亡战士纪念日休市","change":-0.29,"latestTime":"05-22 16:00:00 EDT","open":37.215,"high":37.8,"low":36.64,"amount":25952660,"amplitude":0.031275,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.129138,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1531886400000,"exchange":"NASDAQ","adjPreClose":37.09,"preHourTrading":{"tag":"盘前","latestPrice":37.2,"preClose":37.09,"latestTime":"09:14 EDT","volume":2312,"amount":86280.76504,"timestamp":1779455660567,"change":0.11,"changeRate":0.002966,"amplitude":0.163934},"postHourTrading":{"tag":"盘后","latestPrice":36.8,"preClose":36.8,"latestTime":"16:10 EDT","volume":23539,"amount":866235.2,"timestamp":1779480604911,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8222660860202049,"impliedVol":0.2765,"impliedVolPercentile":0.1116},"requestUrl":"/m/hq/s/CRNX","defaultTab":"news","newsList":[{"id":"1101516072","title":"Crinetics Pharmaceuticals Inc. 预期2026年GAAP运营支出6-6.5亿美元；非GAAP运营支出4.8-5.2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101516072","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101516072?lang=zh_cn&edition=full","pubTime":"2026-05-08 04:29","pubTimestamp":1778185754,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. 公布了其2026财年的财务指引。该公司预计，按照美国通用会计准则（GAAP）计算，其2026年的运营支出将在6亿美元至6.5亿美元之间。同时，根据非美国通用会计准则（Non-GAAP）测算，公司预期的运营支出范围则为4.8亿美元至5.2亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137985690","title":"财报前瞻｜Crinetics Pharmaceuticals Inc.本季度营收预计增5.55倍，看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1137985690","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137985690?lang=zh_cn&edition=full","pubTime":"2026-02-19 12:36","pubTimestamp":1771475790,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.将于2026年02月26日发布最新季度财报，市场关注收入恢复与费用节律对每股收益的影响以及年初融资带来的研发推进节奏。公司主营收入以“授权费”为核心，上季度该科目为45.80万美元，体量小但对总收入的贡献明确，未来变动仍取决于合作里程碑与进度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Crinetics Pharmaceuticals Inc.本季度营收预计增5.55倍，看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113632150","title":"Crinetics启动Atumelnant治疗先天性肾上腺皮质增生症（CAH）的2/3期儿科临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1113632150","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113632150?lang=zh_cn&edition=full","pubTime":"2026-01-23 05:06","pubTimestamp":1769116007,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. (CRNX) 已正式启动一项针对儿科患者的2/3期临床试验，旨在评估其研究性药物Atumelnant用于治疗先天性肾上腺皮质增生症（CAH）的疗效与安全性。该研究的启动标志着公司在该疾病领域研发进程中的重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144961515","title":"Crinetics Pharmaceuticals公布2026年1月根据纳斯达克上市规则5635(C)(4)授予的诱导性股权奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=1144961515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144961515?lang=zh_cn&edition=full","pubTime":"2026-01-13 05:06","pubTimestamp":1768251976,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.（以下简称\"公司\"）近日披露，已依据纳斯达克市场上市规则第5635(C)(4)条，于2026年1月向新入职员工授予诱导性股权奖励。此类奖励作为行业常规人才引进措施，旨在吸引高端科研人才加入研发团队。根据相关规定，该次授予计划无需经过股东大会批准，符合新兴生物科技企业通过股权激励构建核心竞争力的普遍实践。公司强调，此次股权分配严格遵循合规流程，展现了其持续强化代谢疾病创新疗法研发实力的战略决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114259514","title":"Crinetics制药公司宣布拟公开发行普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1114259514","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114259514?lang=zh_cn&edition=full","pubTime":"2026-01-06 05:05","pubTimestamp":1767647101,"startTime":"0","endTime":"0","summary":"圣地亚哥，2026年1月5日——专注于内分泌疾病及内分泌相关肿瘤新型疗法发现、开发和商业化的生物制药公司Crinetics Pharmaceuticals, Inc.今日宣布，计划根据市场及其他条件，通过承销商进行公开发行，拟出售价值3.5亿美元的普通股。此外，公司拟授予承销商为期30天的超额配售选择权，可额外购买最多5250万美元的普通股。本次发行所有股份均由Crinetics出售。本次证券发行依据Crinetics向美国证券交易委员会提交并已自动生效的储架注册声明进行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","CRNX","BK4585","BK4604","BK4555","BK4007","BK4588","TM","03160","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112329282","title":"更正：Crinetics Pharmaceuticals第四季度PALSONIFY美国市场净产品收入突破500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1112329282","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112329282?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:16","pubTimestamp":1767618997,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc.公布最新财务数据，其核心产品PALSONIFY在美国市场第四季度净销售额超过500万美元。这一业绩表现凸显了该药物在目标治疗领域的商业化进展。\n公司此次披露特意澄清了收入统计口径，明确指出相关数字为产品净收入而非季度总收入，同时移除了与IBES预期数据的对比分析。此举旨在更精准地反映产品实际市场表现，为投资者提供清晰的业务进展评估依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRNX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130017232","title":"Crinetics股价盘前攀升2.7% 新药上市推动第四季度营收超500万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1130017232","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130017232?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:08","pubTimestamp":1767618520,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. (CRNX) 股价在盘前交易中上涨2.7%，此前该公司公布其新近上市的药物在第四季度创造了超过500万美元的营收。这一积极表现凸显了市场对该新药商业潜力的初步认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRNX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133602751","title":"Crinetics Pharmaceuticals将公布Palsonify业务进展及Atumelnant治疗先天性肾上腺皮质增生症二期试验第四队列顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133602751","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133602751?lang=zh_cn&edition=full","pubTime":"2026-01-05 05:00","pubTimestamp":1767560414,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. (CRNX) 即将披露其Palsonify项目的战略发展动态，并同步公开Atumelnant针对先天性肾上腺皮质增生症（CAH）开展的二期临床试验中第四患者队列的顶线研究数据。此次更新将涵盖该创新疗法的临床进展与企业商业布局的双重维度，为市场提供关键研发里程碑的最新洞察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRNX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124612366","title":"Crinetics Pharmaceuticals公布2025年12月根据纳斯达克上市规则5635(C)(4)授予的激励补助","url":"https://stock-news.laohu8.com/highlight/detail?id=1124612366","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124612366?lang=zh_cn&edition=full","pubTime":"2025-12-11 05:35","pubTimestamp":1765402509,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals公布2025年12月根据纳斯达克上市规则5635(C)(4)授予的激励补助","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133077077","title":"Crinetics宣布首位患者在1/2期临床试验中接受Crn09682治疗神经内分泌肿瘤及其他表达生长抑素受体2的肿瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1133077077","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133077077?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:06","pubTimestamp":1764767218,"startTime":"0","endTime":"0","summary":"Crinetics宣布首位患者在1/2期临床试验中接受Crn09682治疗神经内分泌肿瘤及其他表达生长抑素受体2的肿瘤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120060913","title":"Crinetics公布首位患者在关键的第三阶段Carefndr试验中随机分组，评估Paltusotine在类癌综合征中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1120060913","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120060913?lang=zh_cn&edition=full","pubTime":"2025-11-21 05:06","pubTimestamp":1763672778,"startTime":"0","endTime":"0","summary":"Crinetics公布首位患者在关键的第三阶段Carefndr试验中随机分组，评估Paltusotine在类癌综合征中的效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123922613","title":"Crinetics Pharmaceuticals宣布根据纳斯达克上市规则5635(c)(4)进行2025年11月诱导性授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1123922613","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123922613?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:20","pubTimestamp":1763572835,"startTime":"0","endTime":"0","summary":"11月11日 - Crinetics Pharmaceuticals Inc.宣布，根据纳斯达克上市规则5635(c)(4)，进行2025年11月的诱导性授予。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112777962","title":"Crinetics Pharmaceuticals 第三季度净收入为-1.30091亿美金","url":"https://stock-news.laohu8.com/highlight/detail?id=1112777962","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112777962?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:02","pubTimestamp":1763571754,"startTime":"0","endTime":"0","summary":"11月6日 - Crinetics Pharmaceuticals 第三季度收入为14.3万美元，而IBES预测为63.72万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517589074","title":"Crinetics Pharmaceuticals, Inc.2024财年实现净利润-2.98亿美元，同比减少38.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517589074","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517589074?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363257,"startTime":"0","endTime":"0","summary":"3月8日，Crinetics Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-2.98亿美元，同比减少38.60%；其中营业收入为1.04百万美元，同比减少74.06%，每股基本收益为-3.69美元。从资产负债表来看，Crinetics Pharmaceuticals, Inc.总负债4.01亿美元，其中短期债务7.15百万美元，资产负债比为4.31，流动比率为0.24。机构评级：截至2025年3月8日，当前有14家机构对Crinetics Pharmaceuticals, Inc.目标价做出预测，其中目标均价为75.64美元，其中最低目标价为55.00美元，最高目标价为100.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000248abed66f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000248abed66f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514904376","title":"Citizens Capital Markets：维持Crinetics Pharmaceuticals(CRNX.US)评级，由优于大市调整至优于大市评级, 目标价由92.00美元调整至91.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514904376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514904376?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:41","pubTimestamp":1740757319,"startTime":"0","endTime":"0","summary":"Citizens Capital Markets：维持Crinetics Pharmaceuticals(CRNX.US)评级，由优于大市调整至优于大市评级, 目标价由92.00美元调整至91.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28234148468148.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171905954","title":"异动解读 | Crinetics制药盘中大涨5.09%,公司上一季度亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1171905954","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171905954?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:22","pubTimestamp":1740756147,"startTime":"0","endTime":"0","summary":"Crinetics制药公司今日盘中大涨5.09%,引发了市场的广泛关注。\n公司日前公布的最新季度业绩显示,2024年第四季度,公司调整后每股亏损为88美分,同比收窄2美分,略好于分析师预期的89美分亏损。尽管如此,公司当季实际亏损8060万美元,同比加大。\n不过,公司当季度业绩整体表现略好于预期,以及分析师看好其长期前景,推动了公司股价今日盘中出现较大涨幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Crinetics制药盘中大涨5.09%,公司上一季度亏损收窄","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125291574","title":"Crinetics Pharmaceuticals 第四季度 GAAP 每股收益 $(0.88)，符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1125291574","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125291574?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:24","pubTimestamp":1740691484,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals  公布季度每股亏损 $，与分析师一致预期相符。这比去年同期每股亏损 $ 增加了 2.22%。以上内容来自Benzinga Earnings专栏，原文如下：Crinetics Pharmaceuticals  reported quarterly losses of $ per share which met the analyst consensus estimate. This is a 2.22 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Crinetics Pharmaceuticals 第四季度 GAAP 每股收益 $(0.88)，符合预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514013011","title":"Crinetics Pharmaceuticals, Inc.盘中异动 急速跳水5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514013011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514013011?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:04","pubTimestamp":1740495849,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时04分，Crinetics Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.14%。Crinetics Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。Crinetics Pharmaceuticals, Inc.公司简介：Crinetics Pharmaceuticals Inc 是一家临床阶段的制药公司，专注于罕见内分泌疾病和内分泌相关肿瘤的新疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225230409962ffa35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225230409962ffa35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRNX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514723677","title":"Crinetics Pharmaceuticals, Inc.盘中异动 下午盘急速下跌5.03%报35.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514723677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514723677?lang=zh_cn&edition=full","pubTime":"2025-02-25 02:14","pubTimestamp":1740420878,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日02时14分，Crinetics Pharmaceuticals, Inc.股票出现异动，股价大幅跳水5.03%。截至发稿，该股报35.58美元/股，成交量50.7495万股，换手率0.55%，振幅5.57%。Crinetics Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.36%。Crinetics Pharmaceuticals, Inc.公司简介：Crinetics Pharmaceuticals Inc 是一家临床阶段的制药公司，专注于罕见内分泌疾病和内分泌相关肿瘤的新疗法的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225021439abdb3f3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225021439abdb3f3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509602460","title":"Crinetics Pharmaceuticals(CRNX.US)获Wolfe Research首次覆盖，给予Peer Perform评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509602460","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509602460?lang=zh_cn&edition=full","pubTime":"2025-02-05 02:19","pubTimestamp":1738693194,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals(CRNX.US)获Wolfe Research首次覆盖，给予Peer Perform评级。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05021947950296.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CRNX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.crinetics.com","stockEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0588},{"period":"3month","weight":-0.1529},{"period":"6month","weight":-0.1414},{"period":"1year","weight":0.2222},{"period":"ytd","weight":-0.2095}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Crinetics Pharmaceuticals, Inc.于2008年11月18日根据特拉华州法律注册成立。该公司是一家临床阶段制药公司，致力于发现，开发和商业化用于治疗罕见内分泌疾病和内分泌相关肿瘤的新药。 内分泌途径的功能是保持体内平衡，并且通常使用通过G蛋白偶联受体或GPCRs起作用的肽激素来调节生理学的许多方面，包括生长，能量，代谢，胃肠功能和应激反应。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.078473},{"month":2,"riseRate":0.5,"avgChangeRate":-0.021565},{"month":3,"riseRate":0.25,"avgChangeRate":-0.056934},{"month":4,"riseRate":0.625,"avgChangeRate":0.06869},{"month":5,"riseRate":0.5,"avgChangeRate":-0.022018},{"month":6,"riseRate":0.571429,"avgChangeRate":-0.001759},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.025463},{"month":8,"riseRate":0.5,"avgChangeRate":0.05546},{"month":9,"riseRate":0.375,"avgChangeRate":0.104829},{"month":10,"riseRate":0.5,"avgChangeRate":0.007484},{"month":11,"riseRate":0.875,"avgChangeRate":0.104868},{"month":12,"riseRate":0.75,"avgChangeRate":0.036899}],"exchange":"NASDAQ","name":"Crinetics Pharmaceuticals Inc.","nameEN":"Crinetics Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Crinetics Pharmaceuticals Inc.(CRNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Crinetics Pharmaceuticals Inc.(CRNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Crinetics Pharmaceuticals Inc.,CRNX,Crinetics Pharmaceuticals Inc.股票,Crinetics Pharmaceuticals Inc.股票老虎,Crinetics Pharmaceuticals Inc.股票老虎国际,Crinetics Pharmaceuticals Inc.行情,Crinetics Pharmaceuticals Inc.股票行情,Crinetics Pharmaceuticals Inc.股价,Crinetics Pharmaceuticals Inc.股市,Crinetics Pharmaceuticals Inc.股票价格,Crinetics Pharmaceuticals Inc.股票交易,Crinetics Pharmaceuticals Inc.股票购买,Crinetics Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Crinetics Pharmaceuticals Inc.(CRNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Crinetics Pharmaceuticals Inc.(CRNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}